Skip to content

The CX-DZ-Ⅱ Intelligent Electroacupuncture Instrument for Neck Pain

The CX-DZ-Ⅱ Intelligent Electroacupuncture Instrument for Neck Pain

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03005301
Enrollment
160
Registered
2016-12-29
Start date
2017-01-31
Completion date
2018-06-30
Last updated
2018-06-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acupuncture, Neck Pain

Keywords

electroacupuncture instrument

Brief summary

The present study is a prospective, two-center, randomized, controlled, open-label, non-inferiority trial evaluating the efficacy and safety of a new intelligent electroacupuncture instrument in treating neck pain caused by cervical spondylosis.

Detailed description

A total of 160 eligible patients will be included in this trial and randomly assigned to experimental group and control group in a 1:1 ratio. In experimental group, selected acupoints will be stimulated by the new intelligent electro-acupuncture instrument; while for control group, electroacupuncture treatment will be accomplished by a pre-existing electro-acupuncture instrument. The duration of treatment will be 2 weeks. The primary outcome is the change of visual analog scale score after one course of treatment. The secondary outcomes are visual analog scale score after each treatment, the responder rate, drug-usage rate of non-steroidal antipyretic analgesics, the occurrence rate of adverse events, defect rate of instrument, and excellent rate of instrument.

Interventions

DEVICEintelligent electroacupuncture instrument

Choice of major points: GB20, GB21, EX-B2, GV14. Choice of adjunct points based on syndrome differentiation. Trial instrument of this study is the CX-DZ-Ⅱ type intelligent electroacupuncture therapeutic instrument.Choice of acupuncture needle: one-off stainless acupuncture needle, which is 25\ 40mm in length and 0.30\ 0,38mm in diameter.Waveform: continuous-wave with frequency of 120\ 250 times per minute and current intensity within patients' tolerance.Treatment time: each treatment time is 30 minutes.

DEVICEHwato electroacupuncture instrument

Choice of major points: GB20, GB21, EX-B2, GV14. Choice of adjunct points based on syndrome differentiation. The Hwato electroacupuncture treatment instrument. Waveform: continuous-wave with frequency of 120\ 250 times per minute and current intensity within patients' tolerance. Treatment time: each treatment time is 30 minutes.

Sponsors

West China Hospital
CollaboratorOTHER
Chengdu University of Traditional Chinese Medicine
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No

Inclusion criteria

* Male or female between 18 and 75 years old. * Subject is diagnosed with CS of neck type or nerve-root type by clinical and medical imaging examination. * A history of recurrent episodes of neck pain (one or more neck pain per month lasting for more than 3 months). * Pain intensity is more than 3 points on a VAS upon recruitment. * Subject or his guardian comprehend the aims of this trial, promise not to accept other relative treatments during the trial, and sign the informed consent.

Exclusion criteria

* Subject has acute neck trauma. * Previous medical history of neck trauma treated by surgery, or neurological deficit, or congenital and developmental spinal disorders, or systemic bone diseases, or systemic joint diseases (e.g. joint slippage). * Subject is diagnosed with carotid artery dissection. * Subject is unable to express clearly self-feelings (e.g. subject with severe cerebrovascular accident sequelae). * Subject has infection in acupuncture region. * A history of acupuncture treatment for neck pain in the previous 1 week. * Use of non-steroidal antipyretic analgesics in the previous 3 days. * Subject has to use central analgesics or narcotic analgesics (e.g. Tramadol, Morphine, Dolantin) during the period of clinic trial. * Use of various ointments or medicinal liquors with functions of promoting blood circulation and/or easing pain. * Use of oral and intravenous medicines with functions of opening blood vessels and providing nutrition to nerve. * Combinations of severe systematic diseases (e.g. a history of myocardial infarction, or severe hepatic and renal dysfunction, or acute infectious diseases, or malignant tumors, or severe mental disturbance diseases in previous 12 months). * Intolerance of acupuncture and electro-acupuncture. * Allergy to acupuncture. * Female in pregnancy or lactation. * Subject participate other clinic trials in previous 3 months. * Subject is considered to be unsuited to this trial by investigators.

Design outcomes

Primary

MeasureTime frame
The change of VAS scores from baseline to the completion of treatment0-2 weeks

Secondary

MeasureTime frame
VAS score after each treatment0-2weeks
Responder rate0-2weeks
Use of non-steroidal antipyretic analgesics0-2weeks
Adverse events0-2weeks

Countries

China

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 2, 2026